South Carolina

  • Sam Patrick posted an article
    Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors see more

    3D-PREDICT Study to investigate potential impact to outcomes for several difficult-to-treat solid tumors

     

    GREENVILLE, SC. – June 20, 2018 – KIYATEC, Inc. today announced the enrollment of the first patients in a U.S. clinical study of its Ex Vivo 3D drug response assay (EV3D™) across several difficult-to-treat solid tumors. The 3D-PREDICT clinical study has been initiated at the Cancer Institute of Greenville Health System (GHS) with the goal of recruiting 640 patients across additional clinical sites to be added in the future.

    The 3D-PREDICT Study is a prospective, open-label, multi-institutional, non-interventional study to validate the EV3D assay for clinical use and to investigate the impact on outcomes for cancer patients with both newly diagnosed and recurrent epithelial ovarian cancer and recurrent high-grade gliomas, which include glioblastomas (GBM). Over the next year or so, the study will expand to include patients with newly diagnosed high-grade gliomas, high-grade rare tumors and triple negative breast cancer. The primary objectives of the study are to establish correlation between assay predicted drug response and patient clinical outcomes, and to measure the potential impact of the assay on therapeutic decision-making. The study is anticipated to continue through 2022. Details on the trial can be found on ClinicalTrials.gov

    The EV3D assay platform assesses a patient’s own cancer cells within a biologically relevant 3D culture microenvironment to provide individualized response prediction to specific therapeutic agents. In this study, the therapeutic agents predicted consist of available, guideline recommended drug options for each cancer type. 

    “As an institution, we’ve supported KIYATEC’s pilot clinical studies by providing over 450 samples of cancer tissues spanning the multiple tumor types they are testing and our clinical investigators are ready to take this important next step,” said Larry Gluck, MD, Medical Director of the GHS Cancer Institute. “Patients with recurrent ovarian cancer and recurrent GBM are among those with the most challenging prognosis at every cancer center around the country. The fact that KIYATEC is offering us a new tool in these very difficult to treat populations is a needle mover for these patients coming to Greenville for their treatment.”

    “Patients with these kinds of newly diagnosed and recurrent cancers simply do not have the luxury of time on their side. Their time, health and money spent on a treatment that is not working can have devastating consequences that we all want to avoid,” said Matthew Gevaert, CEO of KIYATEC. “The commencement of this clinical trial builds upon the success of our pilot studies and represents a significant milestone toward our goal of helping cancer patients receive the best treatment at the earliest possible time.”


    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

     

    About Greenville Health System

    Greenville-based Greenville Health System (GHS) has partnered with Columbia-based Palmetto Health to form a not-for-profit health care delivery system serving 1.2 million patients annually across South Carolina. The new name and graphic identity are expected to be announced later this year. GHS offers patients an innovative network of clinical integration, expertise and technologies through its academic health system, eight medical campuses, tertiary medical center, research and education facilities, community hospitals, physician practices and numerous specialty services. GHS, by itself a 1,627-bed system, is home to 16 medical residency and fellowship programs, as well as partnership efforts such as the University of South Carolina School of Medicine Greenville and the soon-opening Clemson University Center for Nursing, Health Innovation and Research. Visit www.ghs.org for more information.

  • Sam Patrick posted an article
    South Carolina's life sciences industry is booming. Read on for details... see more

    From pharmaceuticals and medical devices to research and laboratory testing, the state's life sciences field is booming.  The Charleston and Lowcountry region is home to many established companies and start-ups making a mark on the biomedical and health industries.  Read on for the full story from Charleston Business Magazine's 2018 State of the Lowcountry Report.

  • Sam Patrick posted an article
    IVC, which produces dietary supplements, prescription and OTC products, is expanding. see more

    Company produces high quality dietary supplements, plus nutritional, prescription and OTC products, for leading U.S. and global retailers and contract customers

     

    GREENVILLE, S.C. June 18, 2018 – International Vitamin Corporation (IVC), which produces high quality dietary supplements along with nutritional, prescription and OTC products, will invest several million dollars and add a significant number of positions to expand operations at its Greenville County, S.C. facilities over the next several years.

    Founded more than 55 years ago, IVC produces high quality dietary supplements for leading food, drug, mass and club retailers in the United States. The company also produces nutritional, prescription and OTC products for contract customers around the world. IVC’s recognized ability to deliver on innovation, quality and supply chain efficiency has enabled IVC to become one of the largest and fastest growing private label nutritional supplement companies in the nutritional marketplace.

    “This expansion of our Greenville County presence represents an important step in the growth of our business,” said Steven Dai, President and CEO for International Vitamin Corporation. 

    “We have found Greenville County and the Upstate a welcoming and pro-business location to expand our business, serve our customers and accelerate IVC’s success as we focus our efforts on meeting growing demand from our customers,” Dai added.  “We appreciate the support of the Greenville Area Development Corporation, the city of Greenville, the South Carolina Department of Commerce, and all who joined to make this announcement a reality.”

    IVC will expand its operations at 4615 Dairy Road and 4611 Dairy Road in Greenville County, already employing more than 380 associates.  IVC will create “a meaningful number of additional skilled and professional positions in Greenville County over the next several years,” said Jill Stambler, Vice President Human Resources.

    “Greenville County is pleased with International Vitamin Corporation's decision to expand its business operations in Greenville County by producing well known dietary supplements and pharmaceutical products to the US and international markets as it has for over 50 years,” said H.G. “Butch” Kirven, Chairman of Greenville County Council. “This expansion means significant additional capital investment by the company here, coupled with a commitment to increasing job opportunities for local citizens.  The company's decision reflects the high caliber of Greenville county's workforce, our low tax rates, and the unparalleled quality of life unique to our area.”

    “IVC’s focus on the vitamins, minerals and supplements market and innovations in both manufacturing and supply chain show that our community continues to be a profitable place to do business,” said City of Greenville Mayor Knox White. “The expansion of their manufacturing facility along the I-85 corridor is further affirmation that Greenville is open for business and we are thankful for the IVC family’s trust and continued investment.”

    Hiring details for the additional positions to be filled will be announced in the near future, according to Stambler.  She adds, “We are currently looking for a number of positions on different shifts.”  Some include: 

    • Set-up Mechanics
    • Material Handlers
    • Operators
    • Turret Drivers
    • Manufacturing Supervisors
    • Warehouse Clerk
    • Warehouse Order Pickers
    • Warehouse Shippers

    Interested candidates may apply directly at the IVC website by visiting http://ivccareers.com.

    For more information about International Vitamins Corporation, visit them at www.ivcinc.com.

     

  • Sam Patrick posted an article
    SCRA Collaboration Center Awards feature numerous life science organizations from across the state. see more

    South Carolina Research Authority’s SCRA-Academia Collaboration Team announces nearly $600,000 in feasibility grants for six projects. The awarded projects encourage collaboration between academic institutions and industry partners to advance commercially relevant research and establish the feasibility of the formation of Collaboration Centers. These Collaboration Centers will be founded for those areas demonstrating a critical mass of talent, infrastructure, financial resources, intellectual property and the prevalence of industry in South Carolina.

    “These Feasibility Grants are the first step in establishing Collaboration Centers, which will garner national recognition for South Carolina, create jobs, engage industry and have an overall positive impact on the state.” said Christine Dixon Thiesing, Director of Academic Programs. “SCRA is fostering the growth of collaboration across academic institutions and between academia and industry through the support of six innovation projects.”

    The Feasibility Grant Awards are the result of the efforts of the SACT, which was formed to deliver outcomes aligned with the Strategic Collaboration Agreement signed by SCRA and the presidents of the state’s research universities. The SACT is composed of representatives from the research universities, comprehensive teaching institutions, technical colleges, industry and SCRA. The SACT is currently evaluating the feasibility of establishing three Collaboration Centers – a Composites Industry Solutions Center, Medical Devices Collaboration Center, and Technology-Enabled Population Health Collaboration Center.

    The list of grant awardees is below:

    Composites Industry Solutions Center:
    Collaboration among Clemson University, Greenville Technical College and industry partners Kistler Instrument Corp., Keyence Corporation of America and Renishaw.

    Medical Devices Collaboration Center:
    Collaboration between the Medical University of South Carolina and Clemson University.

    Technology-Enabled Population Health Collaboration Center:
    Collaboration among the Medical University of South Carolina, Trident Technical College and industry partners Zeriscope, Inc. and Amanda Senior Care.

    Collaboration between Francis Marion University and a regional health organization as the industry partner.

    Collaboration among University of South Carolina – Upstate and industry partners ChartSpan Medical Technologies and a state agency.

    Collaboration among Clemson University, Florence-Darlington Technical College’s Southeastern Institute of Manufacturing and Technology and industry partner Greenville Health System.

  • Sam Patrick posted an article
    ZEUS Industrial has acquired MWC Technologies, LLC see more

    ORANGEBURG, S.C., June 11, 2018 -- Zeus Industrial Products, Inc. (Zeus), a leading polymer extrusion manufacturer and material science innovator, today announced that it has acquired MWC Technologies, LLC (MWC). This adds to the capabilities that Zeus has been developing for the past five decades.

    MWC, a manufacturer of medical device components based in Chattanooga, TN, possesses innovative technologies that support Zeus' growth strategy. This acquisition will allow for the global commercialization of the many cutting-edge, solution-driven products in MWC's portfolio.

    Click to Tweet: @ZeusTubing acquires MWC Technologies: https://www.zeusinc.com/2018/06/11/zeus-acquires-mwc-technologies-llc/


    COMMENTS

    "Since I founded the company in 1966, Zeus has been focused on continuing to grow and innovate. This acquisition supports those goals. We are confident that our acquisition of MWC  will provide value to our customers today and into the future.." – Frank P. Tourville, Sr., Founder and Chairman of the Board, Zeus Industrial Products, Inc.

    "The acquisition of MWC  will expand our capabilities and product portfolio to address the rising demand for advanced precision extrusions. Our combined expertise will enhance our ability to better serve customers around the globe." – John Winarchick, CEO, Zeus Industrial Products, Inc.

    "We are excited to be joining the Zeus team!  Zeus's long term commitment to industry leading quality, customer service and innovation aligns well with MWC's culture.  Our combined technologies will enable new to the market solutions for our customers." – Eric Avans, Quality Manager, MWC Technologies

    RESOURCES

    Zeus Industrial Products: Learn more about the company and its products on the Zeus website; or call toll-free 1-800-526-3842 or +1-803-268-9500 outside the U.S.

    ABOUT ZEUS INDUSTRIAL PRODUCTS, INC.

    Zeus Industrial Products, Inc., is headquartered in Orangeburg, SC, USA. Its core business is the development and precision extrusion of advanced polymeric materials. The company employs over 1,500 people worldwide with manufacturing facilities in Aiken, Gaston and Orangeburg, South Carolina; Branchburg, New Jersey; and Letterkenny, Ireland. Zeus products and services serve companies in the medical, automotive, aerospace, fiber optics, energy and fluid management markets. For more information, visit www.zeusinc.com.

  • Sam Patrick posted an article
    U.S. bioscience industry has reached $2 trillion in annual economic impact while continuing to grow see more

    Boston, MA (June 5, 2018) –  A study released today at the BIO International Convention shows that the U.S. bioscience industry has reached $2 trillion in annual economic impact while maintaining accelerated venture capital investment and job growth numbers. Among U.S. technology sectors, the bioscience industry has held a leading position as an economic driver and job generator.

    The report, Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry 2018, finds U.S. bioscience firms directly employ 1.74 million people, a figure that includes more than 273,000 high-paying jobs created since 2001. The average annual wage for a U.S. bioscience worker reached $98,961 in 2016. These earnings are more than $45,000 greater, on average, than the overall U.S. private sector wage. The report further shows that since 2014, the bioscience industry has grown by 4.4 percent with four of its five major subsectors contributing to this overall job gain.

    For the first time, the biennial report includes a full assessment of the economic impact of the bioscience industry and finds its total economic impact on the U.S. economy, as measured by overall output, totaled $2 trillion in 2016. This impact is generated by the direct output of the bioscience industry combined with the indirect (supply chain) and induced (employee spending) impacts. The industry and its associated economic output support 8 million jobs throughout the entire U.S. economy through both indirect and induced effects.

    “This report highlights the enormous economic impact delivered by our industry. This strong performance is due to the vital and wide-ranging collaborations between industry partners, universities, and policymakers that provides a business climate that supports the development of innovative bioscience products and high paying jobs,” said Jim Greenwood, President and CEO of the Biotechnology Innovation Organization."

    The report also takes the pulse of the broader U.S. innovation ecosystem for bioscience companies and finds it advancing with positive results. The U.S. is experiencing strong gains in bioscience venture capital funding, growth in patents, a recent ramp-up in bioscience-related university R&D expenditures and increasing research funding from the National Institutes of Health (NIH).

    “The bioscience industry is vital to the U.S. not only as an innovation engine that is improving lives, but also as a major economic driver that is consistently generating high-quality jobs and significant economic output across the nation,” said Ryan Helwig, Principal and Project Director with TEConomy Partners.

    The state-by-state industry assessment is the eighth in a biennial series, developed in partnership by TEConomy and BIO, presenting data on national, state, and metropolitan area bioscience industry employment and recent trends.

    Additional highlights from the industry economic analysis include:

    • The industry is a major economic driver and is well distributed across U.S. states and cities:
      • 41 states experienced net job growth in the biosciences between 2014-2016
      • 38 states and Puerto Rico have an employment specialization in at least one bioscience subsector
      • 213 of 383 U.S. metropolitan areas have at least one bioscience specialization

    Highlights from the analysis of the innovation ecosystem for the bioscience industry include:

    • Strength in recent venture capital and patenting trends:
      • Venture capital investments have reached new highs. More than $66 billion in venture capital was invested in bioscience companies during the 2014 through 2017 period, including a new annual high in 2017 at $20 billion invested.
      • Innovation continues to drive the biosciences, since 2014 the U.S. has increased patent totals in bioscience-related technology classes by nearly 5 percent, or 1.6 percent per year, on average. 2017 had a total of nearly 27,000 patents awarded to U.S. inventors, another new high.
    • Growth for academic biosciences R&D in 2016
      • After several years of concerns raised about the declining and/or flat NIH research budgets and the subsequent effects on academic and other research, NIH funding is back on the rise. There have been budget increases sustained each of the last three years.
      • Across America’s colleges and universities, the pace of R&D spending in bioscience-related research areas has increased. Following a 1.5 percent decline in 2015, academic R&D expenditures in the biosciences increased 5.5 percent to $42 billion in 2016.

  • Sam Patrick posted an article
    South Carolina Named Top 3 in Best States for Business see more

    South Carolina has another opportunity to promote its economic development prowess thanks to a magazine’s business climate rankings.

    The Palmetto State tied for third with North Carolina in Chief Executive’s 2018 “Best and Worst States for Business.” Texas was No. 1, followed by Florida. Indiana was fifth.

    “A high ranking like this is a great tool that drives industrial prospects to consider South Carolina and our region for new investment and jobs,” says Will Williams, president and chief executive of the Economic Development Partnership, which serves Aiken, Edgefield, McCormick and Saluda counties.

    It was a slight improvement for the Palmetto State, which finished fourth in 2017. Economic development officials say there’s value in “best” lists.

    “We certainly use these types of rankings in our marketing to differentiate ourselves from other states and regions,” says John Lummus, president and chief executive of the Upstate SC Alliance, which serves a 10-county region. “I feel that these rankings are important not only because they shine a light on the positive, but also often show where improvements may need to be considered.”

    This latest ranking, which is based on a survey of CEOs, is in its 14th year. Publications devoted to business and/or economic development produce various types of state-by-state rankings throughout the year.

    “The Palmetto State consistently scores near the top due to a number of factors, such as low unionization rates, strong cooperation between government and business, low-cost utilities, established transportation and infrastructure, competitive wage rates, and availability of a talented workforce,” Lummus says.

    South Carolina ranked 10th overall in the Chief Executive rankings in 2015, fifth in 2014 and eighth in 2013.

    “This doesn’t just happen by accident,” says David Ginn, president and chief executive of the Charleston Regional Development Alliance. “The S.C. Department of Commerce is one of the best-performing economic development teams in the country.”

    Texas, Florida and North Carolina have been one-two-three for each of the past four years. Texas has been No. 1 all 14 years of the ranking’s existence.

    “The difference between the top five states is negligible, roughly within the statistical margin of error,” says John O’Toole, executive director of the Beaufort County Economic Development Corp.

    Meanwhile, California anchored the bottom of the list at No. 50 for the seventh consecutive year. The seven lowest-ranked states were all the same as in 2017.

    The magazine speculated that the reputations, leadership and governing philosophies in the top and bottom states don’t change much, while states in the middle of the rankings move up and down in response to those factors.

    “Our legislature has provided us tools to be competitive and our state and local permitting agencies understand the importance of keeping it simple,” Williams says. “Our collective economic development team has an enviable global reputation for delivering projects, both big and small, on time. And our focus on existing industry success demonstrates we take good care of you once you get here.”

    This year, the magazine noted that South Carolina was a right-to-work state and cited the South Carolina Innovation Plan, an initiative to support the advanced manufacturing, life sciences, biotech and computer software sectors.

    “In our targeted industries – aerospace, agribusiness, automotive, manufacturing and technology industries – we can compete with any state or nation,” O’Toole says.

    There were three subcategories used in the ranking: taxation/regulation, workforce quality and living environment. South Carolina ranked 10th, 14th and seventh in those three categories, respectively.

    Living environment is a selling point for O’Toole.

    “To punctuate our value proposition, at the end of the day you can be in Hilton Head, Beaufort, Bluffton or Port Royal,” he says. “What could be finer?”

    The Charleston area also makes many “best” lists related to quality of life and tourism.

    “National rankings make great headlines so we use them to grab attention and reinforce our strengths as a globally attractive location for business and talent,” Ginn says.

  • Sam Patrick posted an article
    KIYATEC growth supports upcoming programs to better predict patient response to oncology drugs see more

    GREENVILLE, SC. – May 29, 2018 – KIYATEC, Inc., a privately held company changing the future of cancer care by predicting patient response to oncology drugs prior to treatment, today announced an expansion of its leadership team with the appointment of two industry veterans. Charlene Knape has joined the company as Vice President of Clinical Affairs, and Timothy Decker as Vice President Commercial Operations.

    Mr. Decker, a twenty year industry leader with a proven track record of developing and commercializing oncology diagnostic services and pharmaceuticals, has assumed responsibility for pre-launch commercial strategic development along with tactical planning and execution to drive clinical product launches. Mr. Decker held roles of increasing responsibility in strategic and tactical marketing for a decade at G.D. Searle and Abbott Laboratories before joining Genomic Health, Inc.  Over an eight year span, he played a lead role as Director and Senior Director in the global launch, marketing, reimbursement and sales of Oncotype DX molecular diagnostic tests in breast, colon and prostate cancers. Mr. Decker subsequently served as Vice President of Marketing at Castle Biosciences, Inc., where he drove corporate and pipeline strategy, as well as in-line product strategy and revenue growth for its molecular diagnostic tests in melanoma. He joins the company from Mexico City-based Grupo Fármacos Especializados, where he served as Division Head, Oncology Diagnostics, responsible for developing reimbursement pathways and securing positive coverage decisions among public and private sector payers.

    With more than 25 years of experience working with diagnostic companies, Ms. Knape is responsible for leading the clinical development programs and clinical operations for KIYATEC’s pipeline for ovarian cancer, glioblastoma, rare tumors and triple negative breast cancer. She most recently served as Senior Director, Clinical Development for Inivata, a clinical cancer genomics company utilizing liquid biopsies for comprehensive genomic profiling of tumors. Prior to this, Ms. Knape served in Becton Dickinson’s Corporate Clinical Development group, responsible for global clinical quality and contracts. Ms. Knape spent five years with Micell Technologies as Senior Director of Clinical Affairs where she managed all global clinical activities for first-in-human and CE Marking studies for an implantable cardiovascular device from initiation through successful regulatory submission. As the company’s lead in clinical operations, Ms. Knape also built the team and initiated a 1,400-patient study in Europe and a 400-patient study in China. Previously, Ms. Knape served as Vice President, Clinical Affairs at EndoTex Interventional Systems, led the clinical functions for Avocet Medical and Somnus Medical Technologies and held clinical affairs positions in the Companion Diagnostics and Biorepository at LabCorp.

    “At this pivotal time in the company’s growth, we are thrilled to welcome Charlene and Tim to KIYATEC. These two newly created positions are critical as we expand our clinical programs in key therapeutic areas and further strengthen our plan for the broad adoption of our patient-specific response prediction tests,” said Dr. Matthew Gevaert, CEO of KIYATEC. “Their expertise and industry knowledge is unparalleled and they will be instrumental as KIYATEC continues toward its path of changing the future of cancer care by predicting patient response to chemotherapy before treatment begins. I’m so glad to have Tim and Charlene on our team as we move toward our goal of commercialization and helping patients receive optimal treatment at the earliest possible time.”

    KIYATEC will be attending the American Society of Clinical Oncology (ASCO) meeting being held June 1-5 in Chicago.

    About KIYATEC, Inc.

    KIYATEC is changing the future of cancer care by accurately predicting patient-specific response and non-response to chemotherapy drugs before treatment begins. Wasted time is the enemy of cancer patients and there is currently no way to accurately predict which cancer patients will respond to standard oncology treatments. KIYATEC has developed a validated process to use a cancer patient’s own live cells to accurately predict treatment response prior to beginning treatment.

  • Sam Patrick posted an article
    Italian BioAg Firm Valagro launches $14 million production facility in Orangeburg County, SC see more

    COLUMBIA, S.C. – Valagro, a producer of biostimulants and fertilizers for the agriculture industry, is launching its new production operations in Orangeburg County. The company’s $14 million investment is projected to create 47 new, high-skilled jobs.

    Founded in 1980 and headquartered in the Abruzzo region of Italy, Valagro is a global leader in the world of biostimulants. The company specializes in the production and marketing of specialty nutrients for use in agricultural production and other industrial applications. Valagro operates through its 12 subsidiaries and owns a commercial network covering more than 80 countries worldwide. Providing innovative and effective solutions for plant nutrition and care, the company’s mission is to increase the quantity and quality of plants and harvested crops while enhancing productivity and reducing environmental impact.

    Located at 397 Millennium Drive in Orangeburg, S.C., Valagro’s new, 65,000-square-foot Orangeburg County facility is expected to come online in the third quarter of 2019. Construction is expected to begin in the fourth quarter of 2018.

    For more information on Valagro, visit the company’s website at https://www.valagro.com/en.

    The Coordinating Council for Economic Development has approved job development credits, as well as a $100,000 Rural Infrastructure Fund grant to Orangeburg County to assist with the costs of building construction.
     

    QUOTES

    “The construction of this U.S. production facility greatly supports our ability to better serve some of the most strategically-important markets, such as the U.S., Canada and Mexico. This means fully implementing Valagro’s principle of putting the customer in the center; the new facility will allow us to improve our ability to meet customers’ needs by providing them with a wide range of sustainable and effective nutritional solutions.” –Valagro CEO Giuseppe Natale

    “Today, we celebrate yet another international firm choosing to do business in South Carolina, a further testament to our business-friendly climate and well-trained workforce. I congratulate Valagro and Orangeburg County on this terrific new partnership and look forward to watching it thrive for years to come.” –Gov. Henry McMaster

    “When a new business comes to South Carolina, it speaks volumes not only about our business climate, but also about our workforce. I am excited to see what the future has in store for Valagro and their new home in Orangeburg County.” –Secretary of Commerce Bobby Hitt

    “We welcome Valagro to South Carolina and to Orangeburg County. Valagro is joining one of the state’s top industries, and we’re eager to share our agribusiness-friendly climate with this international company as it builds its new U.S. production facility.” –S.C. Agriculture Commissioner Hugh Weathers

    “South Carolina Ports Authority welcomes Valagro to our state and looks forward to serving its import needs. The Port plays an important role in the international supply chains of manufacturers across our state, and we look forward to supporting their addition to our growing economy.” –S.C. Ports Authority President and CEO Jim Newsome

    “Orangeburg County welcomes Valagro to our community. We are grateful they have chosen Orangeburg County as your first manufacturing facility in the U.S. It is a testament to our skilled workforce, location and pro-business environment. We thank Valagro for their investment in our county and our citizens.” –Orangeburg County Council Chairman Johnnie Wright Sr.

    “I join with the Orangeburg City Council in welcoming Valagro, a leader in the production and marketing of biostimulants and specialty nutrients. Their commitment is a positive reflection of our workforce and will provide quality careers for our citizens. By creating these jobs, 47 families will benefit, and our community will continue to prosper. We look forward to working with the company and celebrating its success.” –Orangeburg Mayor Michael C. Butler

    “We’re delighted that Valagro has selected Orangeburg County for its next facility. The company’s expansion into Orangeburg County is a boon for the local economy and workforce and further confirms South Carolina’s position as a strong competitor in attracting international companies looking to grow their business in the U.S.” –Central S.C. Alliance Chairman Mike Brenan

  • Sam Patrick posted an article
    John Warner of Accessible Diagnostics speaks on the recent SEMDA conference see more

    Mike Switzer of South Carolina Business Review, which airs weekdays on South Carolina Public Radio stations across the Palmetto State, interviews John Warner -- co-founder of Concepts to Companies and founder and CEO of Swampfox, an entrepreneur-centric social media company.  The conversation focuses on the rapid growth of the life sciences industry in South Carolina, and the significance of Greenville, S.C. being selected to host the Southeast Medical Device Association annual conference recently for the first time ever.  Click to hear the interview.

  • Sam Patrick posted an article
    SCRA, SBA form Strategic Alliance to further economic development, innovation see more

    The U.S. Small Business Administration’s S.C. District has partnered with SCRA to form a Strategic Alliance Memorandum.

    The alliance is expected to further economic development through entrepreneurship, educational opportunities and access to capital and technical assistance.

    “We recognize the common goals of SCRA and SBA in helping start, maintain and expand small businesses,” R. Gregg White, S.C. SBA district director, said in a statement. “This is an opportunity to leverage the resources of both organizations for the benefit of South Carolina small businesses.”

    Bob Quinn, SCRA’s executive director, joined White in signing the memorandum at the Applied Technologies Center in Summerville.

    “By supporting entrepreneurs, small businesses and early-stage companies, we are creating opportunities for the citizens of South Carolina,” Quinn said. “We are excited to formalize our relationship with the S.C. SBA and look forward to our future collaborations with their team.”

    SCRA, chartered in 1983, is a public nonprofit that supports entrepreneurs and academic research and connects industry to innovators.

  • Sam Patrick posted an article
    Lita Nelsen named to MUSC Foundation of Research Development Board see more

    CHARLESTON, S.C. (May 7, 2018) – The Medical University of South Carolina (MUSC) Foundation of Research Development (FRD) has elected Lita Nelsen to its board of directors. An international expert in university technology transfer, Nelsen was elected as an at-large member and began her three-year term April 2018.

    “I am honored and excited to be part of the MUSC FRD board as it is embarking on an enhanced effort to bring the results of MUSC research to patients through licensing of patents and new software, collaborative research with industry, and formation of new startup companies based on MUSC research results,” she said.  “The benefits will extend far beyond MUSC itself, to patients, to companies, and to economic development of the region.”

    Having served as Director of the Technology Licensing Office at the Massachusetts Institute of Technology (MIT) for nearly 30 years, Nelsen brings a wealth of unprecedented technology transfer experience to MUSC.  Currently she works as a consultant in licensing, university technology transfer and entrepreneurship in the US, Europe and Asia.       

    FRD board chair Arlene Morris said, “It is a pleasure to welcome Lita to the MUSC FRD Board. Her vast experience with innovation, licensing and consulting will bring a dimension to MUSC that will be helpful as we transition our science to help patients and healthcare providers improve therapies.”

    Amy Salzhauer, managing partner of Charleston-based Good Growth Capital adds, “I had the good fortune of working with Lita when I was starting companies out of MIT; her leadership was an essential part of the development of the entrepreneurial ecosystem at MIT for several decades.  She is a legend in her field.  I am so excited she is bringing her unparalleled expertise and experience to MUSC and to South Carolina.”  

    Nelsen completed bachelor’s and master’s degrees in chemical engineering from MIT, as well as earning a master’s degree in management from MIT as a Sloan fellow. Before her position at MIT, she spent 20 years in industry, primarily in the fields of membrane separations, medical devices, and biotechnology.

    She is widely published, has lectured in and advised universities in at least 20 countries, and has served on many boards including as president of the Association of University Technology. She was also on the board of Mass Ventures (MTDC) for 20 years, and is currently on the scientific advisory boards of Partners’ Investment Fund and the Massachusetts Life Sciences Center. The United Kingdom’s government awarded her the honor of “Member of the Order of the British Empire” (MBE) for her work with technology transfer institutions throughout the UK.

    “Over the past several years we have recruited some of the best technology transfer, industry, and venture capital talent to the FRD Board. We are grateful to have Ms. Nelsen join us and it exemplifies MUSC’s commitment to the commercialization our technologies, “said Michael Rusnak, MUSC FRD executive director.                                                                                

     

    About the MUSC Foundation for Research Development
    MUSC Foundation for Research Development (FRD) has served as MUSC's technology transfer office since 1998. During that period, FRD has filed patent applications on more than 400 technologies, resulting in over 150 U.S. issued patents. Additionally, FRD has executed more than 150 licenses and spun out more than 50 startup companies. MUSC startups have had products approved by the FDA and acquired by publicly traded corporations while attracting substantial investment dollars into South Carolina. Innovations from MUSC, including medical devices, therapies and software, are positively impacting health care worldwide. Please visit us online at http://frd.musc.edu/

     

    About MUSC
    Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and 700 residents in six colleges (Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing, and Pharmacy), and has nearly 14,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.4 billion, with an annual economic impact of more than $3.8 billion and annual research funding in excess of $250 million. MUSC operates a 700-bed medical center, which includes a nationally recognized children's hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center), Level I trauma center, Institute of Psychiatry, and the state’s only transplant center. In 2017, for the third consecutive year, U.S. News & World Report named MUSC Health the number one hospital in South Carolina. For more information on academic programs or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.

     

  • Sam Patrick posted an article
    Southeastern life science organization join forces to promote entire region see more

    SCBIO and six additional Southeastern U.S. life science and medtech groups are joining forces to better promote and advocate for the region.

    The Southeastern Medical Device Association (SEMDA) on Wednesday announced the formation of an alliance with six individual state medtech and life science advocacy groups: BioAlabama, Bio Florida, Georgia Bio, ncbio, Life Science Tennessee and SCBIO.

    “Industry and academic partners simply cannot invest enough in each individual state’s bio advocacy organization — nor travel to each organization’s annual event every single year,” SEMDA executive director Jason Rupp said in a news release.

    “But they can come to SEMDA, where the entire region gathers every year bringing their leading investors, academic and industry partners including the best of their young, innovative, investable companies,” Rupp said.

    No single state in the Southeastern U.S. can match the medical device and life science industry strength of the nation’s major hubs in California, Minnesota and Massacusetts. But taken together, the region is more competitive, according to industry advocates there.

    “We are strongest as a region,” said Russell Allen, president and CEO of Georgia Bio. “If we are to advance medical technologies to improve care, reduce healthcare costs and create new jobs, our state associations must work closely together to connect innovators and share resources.”

    The announcement was made at the inaugural 2018 SEMDA Medtech Conference May 2-4 in Greenville, S.C.

  • Sam Patrick posted an article
    Lonza's $46 million investment expected to create new jobs in Greenwood, SC see more

    Lonza, one of the world’s leading suppliers to the pharmaceutical, biotech and specialty ingredients markets, today announced plans to expand operations in Greenwood County. The company is investing $46 million over the next five years and is expected to generate 30 new jobs as a result.

    Headquartered in Basel, Switzerland, Lonza harnesses science and technology to create products that enhance the overall quality of life for patients and consumers around the world. Through its acquisition of Capsugel in July 2017, Lonza now offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms.

    Lonza’s Greenwood County operations, which are located at 535 North Emerald Road in Greenwood, S.C., produce empty capsules and finished dosage forms for the global biopharma and consumer health and nutrition markets. To expand, the company is adding approximately 50,000 square feet of new manufacturing space, which will enable the firm to produce key nutritional ingredients, among other projects.

    With construction expected to be completed in the second quarter of 2019, hiring for the new positions will take place starting in mid-2018. Those interested in joining the Lonza team should visit the company’s careers page online(link is external).

    The Coordinating Council for Economic Development has approved job development credits, as well as a $300,000 Set Aside grant to Greenwood County to assist with the costs of site work and infrastructure improvements.  
     

    QUOTES

    “Lonza is making a significant investment in our operations in Greenwood, further demonstrating our commitment to providing high-quality products and services to our customers worldwide. Greenwood County is rich with talented, skilled individuals who will enhance our global and regional footprint, particularly in the area of consumer health and nutrition.” –Lonza Specialty Ingredients COO Sven Abend

    “South Carolina’s workforce continues to demonstrate unmatched excellence; and, as a result, global companies like Lonza are growing and thriving here. I look forward to seeing all that these new positions will be able to produce and achieve in the years to come.” –Gov. Henry McMaster

    “The Palmetto State’s life sciences industry continues to expand, showcasing South Carolina’s ability to produce a variety of advanced products. We congratulate Lonza and look forward to their continued success in Greenwood County.” –Secretary of Commerce Bobby Hitt

    “Lonza has been an excellent job provider and a source of economic prosperity for Greenwood County. Their new expansion is exciting and encouraging, as it means their good work will continue to produce positive results for people locally and globally.” –Greenwood County Council Chairman Steve Brown

    “We congratulate our friends at Lonza on today’s expansion announcement. Lonza’s continued growth within Greenwood County speaks to the company’s dedication and commitment to the area and the future of life sciences in South Carolina.” –Greenwood Partnership Alliance Chair Dr. Kristin Manske


    FIVE FAST FACTS

    • Lonza is expanding operations in Greenwood County.
    • $46 million investment to create 30 new jobs.
    • Lonza designs, develops and manufactures a wide range of innovative dosage forms for the biopharmaceutical and consumer health and nutrition industries.
    • The company is adding 50,000 square feet to its Greenwood County facility, which is located at 535 North Emerald Road in Greenwood, S.C.

  • Sam Patrick posted an article
    ZEUS promotes Steve Peterson to President see more

    Steve Peterson has been named president of SCBIO investor group Zeus Industrial Products Inc., a polymer extrusion manufacturer and material science innovation company based in Orangeburg, effective immediately.

    Peterson previously held the position of global head of marketing and sales and senior vice president. He will continue to report to Zeus CEO John Winarchick.

    “Since joining Zeus in 2017, Steve has been leading the global sales and marketing function,” Winarchick said in a news release. “During this time, he has demonstrated exceptional customer focus and leadership. Along with his ample skill set and experience, these capabilities will prove extremely valuable in his new role.”

    Peterson will focus on developing growth strategies and team building.

    "I look forward to leading our 1,500-plus employees around the globe as we continue to deliver top-notch service to our customers,” Peterson said. “I will focus on maintaining the growth momentum Zeus has enjoyed since its inception. I am grateful for the confidence placed in me and am excited to assume this new role.”

    During a career that has spanned more than 20 years, Peterson has held global leadership positions with TE ConnectivitySamsung Electronics and General Electric.